FDA Approves Oxlumo (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1
The Pharma Data
NOVEMBER 24, 2020
0.514 mmol/24 hr/1.73 0.771 mmol/24 hr/1.73 Management options to date were limited to hyperhydration, crystallization inhibitors and, in a minority of patients with a specific genotype, pyridoxine (vitamin B6). Visit OXLUMO.com for more information, including full Prescribing Information. IMPORTANT SAFETY INFORMATION.
52 
Let's personalize your content